PODOFILOX

Post-LOE

podofilox

Design Pharmaceuticals

ANDATOPICALGEL

Approved

Nov 2023

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PODOFILOX (podofilox) by Design Pharmaceuticals is clinical pharmacology mechanism of action treatment of anogenital warts with podofilox results in necrosis of visible wart tissue. Approved for the treatment of mucous membrane warts (see precautions ). First approved in 2023.

Drug data last refreshed 21h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Mechanism of Action Treatment of anogenital warts with podofilox results in necrosis of visible wart tissue. The exact mechanism of action is unknown. Pharmacokinetics In systemic absorption studies in 52 patients, topical application of 0.05 mL of an ethanolic solution…

Indications (1)

the treatment of mucous membrane warts (see PRECAUTIONS )

Company

Worked on PODOFILOX at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.